14 results about "Tensin" patented technology

The present invention provides RNA interference (RNAi) oligonucleotides that inhibit the expression of phosphatase and tensin homolog (PTEN), extracellular vesicles comprising said RNAi oligonucleotides, pharmaceutical compositions comprising said RNAi oligonucleotides or said extracellular vesicles, and uses thereof in the treatment of neurological and CNS disorders, and more particularly to their use for the treatment of spinal cord injury.

The invention discloses a construction method and application of a Lewy small body dementia animal model, and belongs to the technical field of animal model construction. The construction method comprises the following steps: obtaining a phosphatase and tensin homologous gene-induced kinase 1 gene knockout experimental animal A by using a gene editing technology, and carrying out hybrid breeding on the experimental animal A and an Alzheimer disease model experimental animal B simulating beta-amyloid protein (Abeta) pathology, and screening filial generations containing the Alzheimer disease related mutation and pink1 gene knockout at the same time. According to the constructed model, beta amyloid protein is deposited on the basis of pink1 gene knockout, beta-amyloid plaque (A beta) is used for inducing alpha-synuclein protein aggregation, Lewy bodies are widely generated in cortex and hippocampus, the occurrence and development process of DLB is simulated, and a reliable animal model is provided for disease mechanism research and treatment drug screening and development.

Disclosed herein are polypeptide fragments and polynucleotides based on mutant capicua transcriptional repressor (CIC), catenin beta 1 (CTNNB1), v-erb-b2 erythroblastic leukemia viral oncogene homolog B (ERBB2), kirsten rat sarcoma (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), splicing factor 3b subunit 1 (SF3B1), SRY-box transcription factor 17 (SOX17), tumor protein 53 (TP53), and cytomegalovirus (CMV) sequences, vectors, host cells, viruses, methods for generating CD8+ T-cells, and methods of treatment. Also disclosed herein are T-cell receptors (TCRs), polynucleotides, vectors and cells comprising the TCRs, and methods of treatment.

Disclosed are implantable polymers that release therapeutic agents in proximity to a tumor in a patient. In some embodiments, a polyethylene glycol hydrogel can release a STING agonist and / or a CAR-T cell in proximity to a phosphatase and tensin homolog (PTEN)-null triple negative breast cancer (TNBC) in the patient.

The present invention provides RNA interference (RNAi) oligonucleotides that inhibit the expression of phosphatase and tensin homolog (PTEN), extracellular vesicles containing the RNAi oligonucleotides, pharmaceutical compositions containing the RNAi oligonucleotides or extracellular vesicles, and their use in the treatment of neurological disorders and CNS disorders, and more specifically their use for the treatment of spinal cord injury.

Provided are an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a protein coded by the uORF. A potential ORF of 138 bases (45aa-uORF) in the 5′UTR of the PTEN, coding an oligopeptide of 45 amino acids (named PTEN-45aa) plays an important role in the development and progression progress of tumors. Further provided are a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular neuroglioma. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.

The present invention discloses a method for constructing and using an animal model of dementia with Lewy bodies, and belongs to the technical field of animal model construction. The construction method comprises: obtaining a phosphatase and tensin homologous gene-induced kinase 1 gene knockout experimental animal A using gene editing technology, and crossbreeding with an Alzheimer's disease model experimental animal B simulating β-amyloid protein (Aβ) pathology, and screening offspring containing both Alzheimer's disease-related mutations and pink1 gene knockout. The model constructed by the present invention is to deposit β-amyloid protein on the basis of pink1 gene knockout, induce α-synuclein protein aggregation using β-amyloid plaques (Aβ), widely produce Lewy bodies in the cortex and hippocampus, simulate the occurrence and development process of DLB, and provide a reliable animal model for disease mechanism research and therapeutic drug screening and development.

The present invention provides RNA interference (RNAi) oligonucleotides inhibiting expression of Phosphatase and tensin homolog (PTEN), extracellular vesicles comprising the RNAi oligonucleotides, pharmaceutical compositions including the RNAi oligonucleotides or said extracellular vesicles and their use in the treatment of neurological and CNS disorders and, more particularly to their use for the treatment of spinal cord injuries.

Compositions for regeneration of inner cells and for treating hearing loss comprise at least one modulator of mechanistic target of rapamycin (mTOR) sufficient to induce reprogramming proliferation and regeneration of inner ear cells. The composition include, in some instances, an effective amount of one or more phosphatase and tensin homolog (PTEN) inhibitors, MYC / NOTCH modulators, Atonal Homolog 1 (Atoh1) modulators or combinations thereof.

The invention discloses a preeclampsia marker as well as application and a kit thereof. Comprising phosphatase and tension protein (PTEN), and the marker can be used for preparing a serological detection preeclampsia diagnostic reagent or diagnostic tool to perform early screening on preeclampsia risk population and fill the blank of current preeclampsia serological diagnosis. The invention belongs to the technical field of medicine. Furthermore, the invention also provides an ELISA kit for detecting preeclampsia, the sampling means is non-invasive and non-invasive, high-precision endoscope equipment is not needed, the kit can be applied to primary medical institutions, the early diagnosis of preeclampsia and the adoption of prevention means for intervention are facilitated, and the kit has good application value.

Implantable polymers that release a therapeutic agent near a tumor in a patient are disclosed. In some embodiments, a polyethylene glycol hydrogel can release a small molecule, such as a STING agonist, near a phosphatase and tensin homolog (PTEN)-null triple negative breast cancer (TNBC) in the patient.

Disclosed are implantable polymers that release therapeutic agents in proximity to a tumor in a patient. In some embodiments, a polyethylene glycol hydrogel can release a small molecule, like a STING agonist in proximity to a phosphatase and tensin homolog (PTEN)-null triple negative breast cancer (TNBC) in the patient.

Implantable polymers that release a therapeutic agent near a tumor in a patient are disclosed. In some embodiments, a polyethylene glycol hydrogel can release a STING agonist and / or CAR-T cells near a phosphatase and tensin homolog (PTEN)-deficient triple negative breast cancer (TNBC) in the patient.

The present invention relates to a compound of the formula (I) wherein the substituents R1, R2, R3 and R4 are as defined in the disclosure of this invention. Said compounds are for treating brain cancer, wherein brain cancer is glioblastoma and such glioblastoma is Phosphatase and Tensin Homolog deleted on Chromosome 10 or PTEN.